Mahkam Tavallaee, MD
Obstetrics/Gynecology · Berkeley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 4
- Since medical school
- 22 years
- Graduated 2004
Offices
4 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: Eden Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Tavallaee’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A154555 · Current
Licensed to practise in California · since 2018 · expires 2027-06-30 · Shahid Beheshti University of Medical Sciences.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$27,843
Medicare paid this office $27,843 for 147 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 58 | $6,349 | $82 |
| Return visit (30+ min) | 38 | $4,603 | $105 |
| New patient visit (45+ min) | 30 | $4,322 | $144 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 66 | $3,126 | $47 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 36 | $2,042 | $57 |
Procedures year by year
| Procedure | 2023 | 2024 |
|---|---|---|
| Biopsy of lining of uterus | 22 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
147 Original Medicare patients in 2024. Average age 71 · Women 100% · Also on Medicaid 20% · Health risk score 0.80. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 46% · Depression 19% · Diabetes 18% · Cancer 16% · Chronic kidney disease 13% · Coronary heart disease 12% · COPD 8% · Atrial fibrillation 7%.
The office billed $206,640, Medicare allowed $35,628 and paid $27,843; for 616 services of 28 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 147 | 616 | 71 | 0.80 | $206,640 | $27,843 |
| 2023 | 129 | 280 | 71 | 1.12 | $102,910 | $25,948 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 41 | $5,988 | $120 |
| New patient visit (45+ min) | 40 | $5,970 | $149 |
| Short return visit (20+ min) | 36 | $3,753 | $80 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 53 | $2,485 | $47 |
| Biopsy of lining of uterus | 21 | $2,092 | $95 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 32 | $1,749 | $55 |
Drugs they prescribed that Part D paid
$85,330
Pharmacies billed $85,330 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
506 generic and 115 brand-name prescriptions · $85,330 in drug cost · 16 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Premarin | 37 | $16,338 | $442 |
| Estradiol | 129 | $13,942 | $108 |
| Estring | 20 | $10,657 | $533 |
| Yuvafem | 50 | $10,009 | $200 |
| Estradiol (Twice Weekly) | 24 | $3,774 | $157 |
See all 14 drugs
| Premarin | 37 | $16,338 | $442 |
| Estradiol | 129 | $13,942 | $108 |
| Estring | 20 | $10,657 | $533 |
| Yuvafem | 50 | $10,009 | $200 |
| Estradiol (Twice Weekly) | 24 | $3,774 | $157 |
| Tolterodine Tartrate Er | 20 | $2,989 | $149 |
| Estradiol (Once Weekly) | 27 | $2,550 | $94 |
| Progesterone | 45 | $1,838 | $41 |
| Dotti | 16 | $1,563 | $98 |
| Clobetasol Propionate | 38 | $1,046 | $28 |
| Clotrimazole-Betamethasone | 32 | $856 | $27 |
| Gabapentin | 13 | $157 | $12 |
| Triamcinolone Acetonide | 12 | $40 | $3 |
| Alendronate | 19 | $33 | $2 |
Year by year
| 2024 | 621 | 195 | None | 19% | $85,330 |
| 2023 | 359 | 154 | None | 23% | $50,164 |
| 2020 | 42 | 21 | 38% (16) | None | $1,561 |
| 2018 | 19 | 15 | 68% (13) | 0% | $124 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Premarin | 19 | $8,449 | $445 |
| Estring | 15 | $8,244 | $550 |
| Estradiol | 64 | $7,297 | $114 |
| Yuvafem | 13 | $2,753 | $212 |
| Estradiol (Once Weekly) | 19 | $2,507 | $132 |
| Tolterodine Tartrate Er | 23 | $2,021 | $88 |
| Progesterone | 25 | $1,281 | $51 |
| Clotrimazole-Betamethasone | 26 | $1,034 | $40 |
| Clobetasol Propionate | 22 | $489 | $22 |
| Fluconazole | 18 | $79 | $4 |
| Misoprostol | 14 | $26 | $2 |
2018: 1 drug
| Tramadol | 12 | $38 | $3 |
Money from drug and device companies
$27 in 2024
| 2024 | 1 | 1 | None | $27 |
| 2022 | 2 | 8 | None | $140 |
| 2021 | 3 | 17 | $1,200 | $1,846 |
| 2019 | 1 | 1 | None | $325 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma US | Veozah | $27 | 1 payment
|
See the published payment
| Astellas Pharma US | Meals · 2024-10-21 | Veozah | $27 |
See earlier years (2022, 2021, 2019)
2022: $140
| Abbvie | Orilissa | $72 | 4 payments
|
| Myovant Sciences | Myfembree | $67 | 4 payments
|
2021: $1,846
| Medicaroid | Hinotori | $1,365 | 2 payments
|
| Medical Device Business Services | None | $325 | 1 payment
|
| AbbVie | Orilissa | $156 | 14 payments
|
2019: $325
| Medical Device Business Services | None | $325 | 1 payment
|
Professional record
- NPI
- 1891150397
- Licence
- CA 154555California A154555: Current · expires 2027-06-30
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X); Hospitalist (208M00000X)
- Mailing address
- 300 Pasteur Dr Rm L235, Stanford, CA, 94305
- NPI first listed
- 2015-12-28
- NPI last updated
- 2025-05-01
- NPI record certified
- 2025-05-01
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr Rm L235, Stanford, CA, 94305